Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.53 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1952580 | 0.90 | MET (0.53) | METACHENPC1RAB9A | |
| SCHEMBL1950388 | 0.87 | MET (0.55) | METBMPR1AACVRL1ACVR1NPC1 | |
| SCHEMBL13492824 | 0.86 | MET (0.54) | METACHESRCNPC1RAB9A | |
| SCHEMBL1952590 | 0.85 | MET (0.55) | METBMPR1AACVRL1ACVR1 | |
| SCHEMBL19267218 | 0.84 | MET (0.52) | METACHESRCNPC1RAB9A | |
| SCHEMBL1951169 | 0.84 | MET (0.57) | METSRCNPC1RAB9A | |
| SCHEMBL12547398 | 0.82 | MET (0.54) | METACHESRCNPC1RAB9A | |
| SCHEMBL1581624 | 0.82 | MET (0.54) | METSRCNPC1RAB9A | |
| SCHEMBL1579383 | 0.82 | MET (0.60) | METNPC1RAB9A | |
| SCHEMBL12547779 | 0.81 | MET (0.54) | METSRCNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435986-B2 | Bicyclic traizole derivatives for treating of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-06-09 | — | — | US | disclosed |
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | RET, BMX, ERBB2 | MET 11/4885BMPR1A 860/4885ACVRL1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.